Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 10/2017

01-10-2017 | Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

Authors: Patrick F. Frias, Juan Pablo Frias

Published in: Current Diabetes Reports | Issue 10/2017

Login to get access

Abstract

Purpose of Review

The purpose of this review was to review advances in basal insulin formulations and new treatment options for patients with type 2 diabetes not achieving glycemic targets despite optimized basal insulin therapy.

Recent Findings

Advances in basal insulin formulations have resulted in products with increasingly favorable pharmacokinetic and pharmacodynamic properties, including flatter, peakless action profiles, less inter- and intra-patient variability, and longer duration of activity. These properties have translated to significantly reduced risk of hypoglycemia (particularly during the night) compared with previous generation basal insulins. When optimized basal insulin therapy is not sufficient to obtain or maintain glycemic goals, various options exist to improve glycemic control, including intensification of insulin therapy with the addition of prandial insulin or changing to pre-mixed insulin and, more recently, the addition of a GLP-1 receptor agonist, either as a separate injection or as a component of one of the new fixed-ratio combinations of a basal insulin and GLP-1 RA.

Summary

New safer and often more convenient basal insulins and fixed ratio combinations containing basal insulin (and GLP-1 receptor agonist) are available today for patients with type 2 diabetes not achieving glycemic goals. Head-to-head studies comparing the latest generation basal insulins are underway, and future studies assessing the fixed-ratio combinations will be important to better understand their differentiating features.
Literature
1.
Shulman G, Barrett E, Sherwin R. Integrated fuel metabolism. In: Porte D, Sherwin R, Baron A, editors. Ellenberg and Rifkin’s Diabetes Mellitus: The McGraw-Hill Companies; 2003.
2.
Ahern B, Taborsky GJ. Beta-cell function and insulin secretion. In: Porte D, Sherwin R, Baron A, editors. Ellenberg and Rifkin’s Diabetes Mellitus: The McGraw-Hill Companies; 2003.
3.
4.
Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta cell function in subjects spanning the range from normal glucose tolerance to overt diabetes mellitus: a new analysis. J Clin Endocrinol Metab. 2005;90:493–500.CrossRefPubMed
5.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38:140–9.CrossRefPubMed
6.
American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec 8. In standards of medical Care in Diabetes – 2017. Diabetes Care. 2017;40(Suppl. 1):S64–74.CrossRef
7.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2016;22:84–113.CrossRefPubMed
8.
• Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piotti P, Sersclat P, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus Lixisenatide, versus insulin glargine and Lixisenatide Monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39:2026–35. This study demonstrates the benefits of the fixed-ratio combination IGlarLixi versus IGlar U-100 and lixisenatide in patients with type 2 diabetes suboptimally controlled on oral antidiabetic agents.
9.
• Aroda V, Rosenstock J, Wysham C, Unger J, Bellido D, Gonzalez-Galvez G, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus Lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2015;39:1972–80. This study demonstrates the benefits of the fixed-ratio combination IGlarLixi versus IGlar U-100 in patients with type 2 diabetes suboptimally controlled on basal insulin with or without oral antidiabetic agents. CrossRef
10.
• Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–93. This study demonstrates the benefits of the fixed-ratio combination IDegLira versus IDeg and liraglutide in patients with type 2 diabetes suboptimally controlled on oral antidiabetic agents.
11.
• Buse J, Vilsbøll T, Thurman J, Blevins T, Langbakke I, Bøttcher S, et al. Contribution of Liraglutide in the fixed-ratio combination of insulin Degludec and Liraglutide (IDegLira). Diabetes Care. 2014;37:2926–33. This study demonstrates the benefits of the fixed-ratio combination IDegLira versus IDeg in patients with type 2 diabetes suboptimally controlled on basal insulin with or without oral antidiabetic agents.
12.
Lantus [package insert]. Bridgewater. Sanofi-Aventis; 2015.
13.
Levemir [package insert]. Princeton: Novo Nordisk; 2005.
14.
Toujeo [package insert]. Bridgewater: Sanofi-Aventis; 2015.
15.
Tresiba [package insert]. Plainsboro: Novo Nordisk; 2016.
16.
Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950–5.CrossRefPubMed
17.
Garber AJ, Clauson P, Pedersen CB, Kølendorf K. Lower risk of hypoglycemia with insulin Detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007;55:1735–40.CrossRefPubMed
18.
Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–67.
19.
Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175–84.CrossRefPubMed
20.
Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013;30:1009–18.CrossRefPubMedPubMedCentral
21.
Søeborg T, Rasmussen CH, Mosekilde E, Colding-Jørgensen M. Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci. 2009;36:78–90.CrossRefPubMed
22.
Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19:3–12.CrossRefPubMed
23.
Lucidi P, Porcellati F, Andreoli AM, Carriero I, Candeloro P, Cioli P, et al. Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: the importance of appropriate resuspension before subcutaneous injection. Diabetes Care. 2015;38:2204–10.CrossRefPubMed
24.
Humulin® N [package insert]. Indianapolis : Eli Lilly & CO; 2015.
25.
Novolin® N [package insert]. Princeton: Novo Nordisk A/S; 2010.
26.
Hilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs. 2014;74:911–27.CrossRefPubMedPubMedCentral
27.
Owens DR. Insulin preparations with prolonged effect. Diab Tech and Thera. 2011;13(Suppl 1):S5–S14.
28.
Basiglar [package insert]. Indianapolis. Eli Lilly & CO; 2016.
29.
Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK, Zielonka JS, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17:734–41.CrossRefPubMed
30.
31.
Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498–504.
32.
Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units.mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units.mL−1. Diabetes Care. 2015;38:637–43.PubMed
33.
Drab SR, Philis-Tsimikas A. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action. Pharmacotherapy. 2014;34:291–302.CrossRefPubMed
34.
Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032–9.CrossRefPubMedPubMedCentral
35.
Riddle M, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–6.CrossRefPubMed
36.
Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–74.CrossRefPubMed
37.
Rosenstock J, Davies M, Home P, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408–16.CrossRefPubMedPubMedCentral
38.
• Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. EDITION 1 study investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–62. This study demonstrates the benefits of IGlar U-300 versus IGlar U-100 in patient with type 2 diabetes. CrossRefPubMed
39.
Yki-Jarvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–43.CrossRefPubMed
40.
Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386–94.CrossRefPubMedPubMedCentral
41.
• Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN once long). Diabetes Care. 2012;35:2464–71. This study demonstrates the benefits of IDeg versus IGlar U-100 in patient with type 2 diabetes. CrossRefPubMedPubMedCentral
42.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498–507.CrossRefPubMed
43.
Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen L, et al. Effects of insulin degludec vs insulin glargine U100 of hypoglycemia in patients with type 2 diabetes. The SWITCH 2 randomized clinical trial. JAMA. 2017;318:45–56.CrossRefPubMed
44.
Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858–64.CrossRefPubMedPubMedCentral
45.
•• Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; doi:10.​1056/​NEJMoa1615692. This long-term, large-scale study demonstrates the cardiovascular safety of IDeg, as well as lower risk of severe hypoglycemia versus IGlar U-100 in patients with type 2 diabetes.
46.
47.
Lambert K, Hold RIG. The use of insulin analogues in pregnancy. Diabetes Obes Metab. 2013;15:888–900.CrossRefPubMed
48.
Toledano Y, Hadar E, Hod M. Safety of insulin analogues as compared with human insulin in pregnancy. Expert Opin Drug Saf. 2016;15:963–73.CrossRefPubMed
49.
Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes. 1995;44:165–72.CrossRefPubMed
50.
Holman R, Thorne K, Farmer A, Davies M, Keenan J, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–30.
51.
Holman R, Farmer A, Davies M, Levy J, Darbyshire J, Keenan J, et al. For the 4-T study group three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.
52.
53.
Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes Metab. 2012;14:228–33.CrossRefPubMed
54.
Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016;121:17–26.CrossRefPubMed
55.
Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34.CrossRefPubMed
56.
Berlie H, Hurren KM, Pinelli NR. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes Metab Syndr Obes. 2012;5:165–74.PubMedPubMedCentral
57.
Soliqua [package insert]. Bridgewater: Sanofi-Aventis; 2016.
58.
Xultophy [package insert]. Plainsboro: Novo Nordisk; 2016.
59.
Suliqua [package insert]. Paris: Sanofi-Aventis; 2017.
60.
Xultophy [package insert]. Bagsvaerd: Novo Nordisk; 2014.
Metadata
Title
New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin
Authors
Patrick F. Frias
Juan Pablo Frias
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 10/2017
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-017-0926-8

Other articles of this Issue 10/2017

Current Diabetes Reports 10/2017 Go to the issue

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

The Role of Epigenetics in Type 1 Diabetes

Obesity (J McCaffery, Section Editor)

Weight Management in Patients with Type 1 Diabetes and Obesity

Therapies and New Technologies in the Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Management of Type 1 Diabetes in the Hospital Setting

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Tolerogenic Nanoparticles to Treat Islet Autoimmunity

Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)

Diabetic Eye Screening: Knowledge and Perspectives from Providers and Patients

Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)

Diameter Changes of Retinal Vessels in Diabetic Retinopathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits